BioSpace News Archive

Acentrus Specialty™, a national network of health systems and hospitals committed to providing specialty pharmacy care for their patients, has finalized an agreement with Puma Biotechnology, Inc.

Antares Pharma, Inc., a pharmaceutical technology company, announced the first commercialization of the Company’s multi-dose pen platform launched in Europe.

Phase 2 Trial for Patients with Solid Tumors of Any Origin Bearing NRG1 Fusions

DiNAQOR AG, a gene therapy platform company, announced the expansion of its global research and development operations with a new facility in the Bio-Technopark Schlieren-Zürich.

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced the appointment of Michele Korfin as chief operating and chief commercial officer. Ms. Korfin brings over 20 years of experience in oncology, focused on business operations and commercialization of novel therapies. In this role, she will have oversight of manufacturing and comm

Grant to fund ongoing preclinical research for important proof-of-principle non-human studies in preparation for human gene therapy clinical trials

Newly-Appointed CFO Andrew Schmidt Brings Extensive and Wide-Ranging Public Company Experience

Afya Limited, or Afya announced the acquisition of 100% of the total share capital of PEBMED, through its wholly-owned subsidiary Afya Participações S.A.

Gilead to Acquire 49.9% Equity Interest in Tizona – – Gilead Will Have Right to Acquire Remainder of Tizona for up to $1.25 Billion in Potential Option Fees and Future Milestone Payments – – Gilead Research and Development Funding to Accelerate Tizona’s First-in-Class Pipeline –

Full Results of Aimmune’s Pivotal Phase 3 European ARTEMIS Trial of PALFORZIA ® Published in The Lancet Child & Adolescent Health -- Peanut-Allergic Patients Treated with PALFORZIA Showed Desensitization to Peanut Protein with a Predictable Safety Profile at Nine Months – --Clinically Meaningful Improvements in Food Allergy Quality of Life Were Reported in all Age Groups -- BRISBANE, Calif.--( BUSINESS WIRE )-- Aimmune Therapeutics, Inc.